Analysts predict that CytomX Therapeutics Inc (NASDAQ:CTMX) will post sales of $15.69 million for the current quarter, Zacks reports. Four analysts have made estimates for CytomX Therapeutics’ earnings. The highest sales estimate is $22.92 million and the lowest is $5.00 million. CytomX Therapeutics posted sales of $11.47 million during the same quarter last year, which suggests a positive year-over-year growth rate of 36.8%. The business is scheduled to announce its next quarterly earnings report on Wednesday, February 26th.
According to Zacks, analysts expect that CytomX Therapeutics will report full year sales of $64.90 million for the current year, with estimates ranging from $54.20 million to $72.13 million. For the next year, analysts forecast that the firm will report sales of $51.05 million, with estimates ranging from $40.00 million to $64.80 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for CytomX Therapeutics.
CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.13). CytomX Therapeutics had a negative net margin of 163.18% and a negative return on equity of 90.62%. The business had revenue of $10.71 million for the quarter, compared to analysts’ expectations of $23.58 million.
Several equities research analysts recently weighed in on the company. BidaskClub cut CytomX Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, October 1st. Guggenheim assumed coverage on CytomX Therapeutics in a research note on Wednesday, November 27th. They issued a “buy” rating and a $16.00 price target on the stock. Zacks Investment Research downgraded CytomX Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 15th. Nomura reissued a “buy” rating and set a $22.00 price objective on shares of CytomX Therapeutics in a research note on Sunday, August 11th. Finally, Wedbush cut shares of CytomX Therapeutics from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $25.00 to $8.00 in a report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $18.56.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CTMX. First Trust Advisors LP purchased a new position in shares of CytomX Therapeutics during the first quarter valued at approximately $263,000. Strs Ohio boosted its holdings in CytomX Therapeutics by 7.5% in the second quarter. Strs Ohio now owns 59,900 shares of the biotechnology company’s stock valued at $672,000 after acquiring an additional 4,200 shares in the last quarter. Aperio Group LLC purchased a new position in CytomX Therapeutics during the 2nd quarter valued at $70,000. DekaBank Deutsche Girozentrale increased its position in CytomX Therapeutics by 64.6% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 24,200 shares of the biotechnology company’s stock valued at $257,000 after purchasing an additional 9,500 shares during the period. Finally, Candriam Luxembourg S.C.A. raised its holdings in CytomX Therapeutics by 2.8% in the 2nd quarter. Candriam Luxembourg S.C.A. now owns 687,833 shares of the biotechnology company’s stock worth $7,684,000 after purchasing an additional 19,000 shares in the last quarter. Institutional investors and hedge funds own 78.89% of the company’s stock.
Shares of CTMX traded up $0.16 during trading hours on Monday, hitting $6.29. The company had a trading volume of 283,934 shares, compared to its average volume of 439,568. CytomX Therapeutics has a 52-week low of $5.10 and a 52-week high of $19.75. The company has a quick ratio of 4.40, a current ratio of 4.40 and a debt-to-equity ratio of 0.31. The stock’s 50 day moving average price is $6.17 and its 200 day moving average price is $8.88. The firm has a market cap of $285.78 million, a P/E ratio of -3.10 and a beta of 0.64.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
See Also: What is the operating income formula?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.